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Abstract
Protein kinase D2 (PKD2) is a serine/threonine kinase that belongs to the PKD family of calcium–calmodulin kinases,
which comprises three isoforms: PKD1, PKD2, and PKD3. PKD2 is activated by many stimuli including growth factors,
phorbol esters, and G-protein-coupled receptor agonists. PKD2 participation to uncontrolled growth, survival,
neovascularization, metastasis, and invasion has been documented in various tumor types including pancreatic, colorectal,
gastric, hepatic, lung, prostate, and breast cancer, as well as glioma multiforme and leukemia. This review discusses
the versatile functions of PKD2 from the perspective of cancer hallmarks as described by Hanahan and Weinberg.
The PKD2 status, signaling pathways affected in different tumor types and the molecular mechanisms that lead to
tumorigenesis and tumor progression are presented. The latest developments of small-molecule inhibitors selective for PKD/
PKD2, as well as the need for further chemotherapies that prevent, slow down, or eliminate tumors are also discussed in this
review.
Introduction
Protein kinases comprise a gene family of 538 members in
the human genome [1] and have been involved in a multi-
tude of complex cellular functions and pathways. Despite
their diverse functions, protein kinases adopt a strikingly
similar active conformation of the catalytic domain [2, 3]
catalyzing the transfer of the γ-phosphate of adenosine
5’-triphosphate (ATP) to the substrate’s hydroxyl group of
either serine, threonine, or tyrosine residues through a
process called phosphorylation. Protein phosphorylation
regulates most aspects of cell life [4] and deregulation of
this process via dysfunctional kinase activity has crystal-
lized as a major mechanism by which tumor cells escape
normal physiological constraints on survival and growth
[5]. Protein kinase D (PKD) family comprises three highly
conserved enzymes in humans: PKD1, PKD2, and PKD3.
The evolution of these isoforms appears to be associated
with the evolution of vertebrates. Although only two PKD
members are expressed in ﬁsh, amphibians, and birds, all
three PKD isoforms are expressed in mammals. PKD iso-
form found in amphibians and ﬁsh most closely resembles
mammalian PKD1, whereas the invertebrate PKD found in
Drosophila is most closely homologous with PKD3. By
contrast, PKD2 seems to have evolved from mammals
onwards [6]. PKD1 and PKD2 are the most closely related
of the three mammalian PKD isoforms and share similar
regulatory molecular mechanisms in various cell types.
Members of the PKD family are effectors of diacylglycerol
(DAG) signaling and are (often) activated downstream of
protein kinase C by multiple stimuli including growth fac-
tors and hormones. They are implicated in various func-
tions, both physiological and pathological, such as cell
viability and proliferation, growth and differentiation,
intracellular trafﬁcking and regulation of the Golgi com-
plex. Several reports described an essential role of PKD
isoforms in carcinogenesis and tumor progression. Impor-
tantly, PKD members can display tissue-dependent
expression and perform isoform-speciﬁc functions in dif-
ferent contexts. So far, many studies of PKD function do
not specify the PKD isoform studied. Since molecular
cloning and ﬁrst characterization of human PKD2 in our
laboratory 16 years ago, a compelling body of evidence on
the role of this kinase in tumorigenesis and cancer pro-
gression has accumulated. The current review aims to
summarize, integrate, and present most of these ﬁndings
under the aspects of the basic principles in cancer biology.
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Protein structure and regulation
PKD was cloned and characterized in the mid of 1990s [7, 8].
Due to the presence of two phorbol ester and DAG C1-binding
domains, PKD was initially regarded by one group as a
member of protein kinase C family and termed PKCµ. PKCµ
was included in the group of the atypical protein kinase C
(aPKC: ξ and ι) that together with the classical protein kinase
C (PKC) members (PKCs: α, β1, β2, and γ) and the novel
PKCs isoforms (nPKCs: δ, η, ε, and ϕ) form a superfamily of
serine/threonine kinases implicated in the regulation of growth,
differentiation, transformation, and apoptosis. However, care-
ful examination of the catalytic domain of PKD/PKCµ
revealed that the kinase domains show little similarity to the
highly conserved regions of the kinase subdomains of the
PKC family but are rather related to the Ca2+/calmodulin-
dependent protein kinase II-like protein kinases [1]. Further-
more, the substrate speciﬁcity of PKD/PKCµ [7, 9] and its
sensitivity to inhibitors [8] are unlike those of the PKC family.
Therefore, the members of the PKD family were considered as
a distinct family of protein kinases belonging to the Ca2+-
/calmodulin-dependent protein kinase (CAMK) group, later
named PKD1. The PKD family also included two other iso-
forms, PKD2 [10] and PKD3 (PKCν) [11, 12]. All three
isoforms of this kinase family share similar structural features
such as the highly conserved N-terminal regulatory domain
containing two cysteine-rich DAG-binding C1 domains and an
auto-inhibitory pleckstrin homology (PH) domain (Fig. 1).
Interestingly, PKD1 and PKD2 share ~85% overall identity at
the amino-acid level and display an even higher degree of
homology in their catalytic domain and C1 domains, which
represent the key for controlling the intracellular localization of
these kinases. The C1 domains are also thought to be involved
in the regulation of PKD activity. Interestingly, however,
although deletion of the C1 domains in PKD1 results in ele-
vated kinase activity, similar deletions in PKD2 abrogate its
activity. The N-terminal regulatory domain also contains a
pleckstrin homology domain involved in auto-inhibition.
Partial deletions or a full ablation of the PH domain results in
increased kinase activity [13, 14]. The PKD2 mRNA is widely
expressed and encodes an 878-amino-acid protein of 105 kDa.
C1a/C1b domain plays a complex role in the regulation of
nucleocytoplasmic shuttling [15]. PKDs are regulated by
phosphorylation. For PKD2, several phosphorylation sites
have been identiﬁed including Ser706 and Ser710—in the
activation loop corresponding to Ser744 and Ser748 in PKD1
[16] and an autophosphorylation site at Ser876, corresponding
to Ser916 in PKD1 [10]. The latter phosphorylation site is not
present in PKD3 (Fig. 1). PKD2 is also phosphorylated at
Ser244 by casein kinase 1, which results in nuclear import
[17]. Furthermore, PKD2 is also shown to be regulated via the
phosphorylation of several tyrosine residues. For example,
PKD2 is phosphorylated at Tyr717 in the P+ 1 loop by Abl in
oxidative stress conditions in an isoform-speciﬁc manner,
which results in increased kinase activity [18]. Tyr87 phos-
phorylation has also been shown in oxidative stress conditions
and was thought to be necessary for PKCδ-mediated PKD2
activation in oxidative stress conditions, but recent data sug-
gest that this event might be superﬂuous to this extent.
Canonical activation of PKD is induced by PKC through the
phosphorylation of Ser706/710 in the activation loop [19]. As
for PKD1, PKD2 becomes activated downstream of G-
protein-coupled receptors through the activation of PLCγ,
which in turn activates PKCα, PKCε, or PKCη [16]. PKD2
can also be activated by gastrin via the cholecystokinin B
receptor [16, 20], hypoxia [21], and by insulin-like growth
factor (IGF)-1 [22].
Protein expression and function
In contrast to PKD1, a high steady-state expression level of
PKD2 was demonstrated in human pancreas, lung, heart,
smooth muscle, and brain [8, 10], whereas kidney and liver
display lower levels of PKD2 mRNA. This suggests that
various members of PKD family exhibit tissue-speciﬁc
expression. In fast proliferating tissues, such as testis and
colonic crypts, an augmented expression of PKD2 was
Fig. 1 Molecular architecture of
protein kinase D family
members: PKD1/PKCµ, PKD2,
and PKD3/PKCν. Adapted from
Rykx et al. [12]
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detected [10]. Additionally, mouse PKD2 but not PKD1, was
speciﬁcally expressed in T- and B-lymphocytes that comprise
the thymus, spleen, and lymph nodes [6]. As PKD1 and PKD2
have a similar (but not identical) molecular weight and are
recognized by the same C-terminal antibodies, many older
studies of PKD function did not specify which PKD isoform
was investigated. Various adult tissues and cell lines show that
different PKD isoforms are in some instances functionally
redundant. For example, multiple PKD isoforms appear to
regulate Golgi organization [23], protein transport [23-26],
nuclear factor-kappa B (NF-κB)-dependent cell survival
response [13, 27, 28], and release of chemokines by Toll-like
receptor-activated epithelial cells [29]. However, there are
examples of cells/tissues where expression of a single PKD
isoform appears to be predominant suggesting a speciﬁc and
non-redundant role of a particular member of PKD family.
Such an example is the role of PKD1 in regulating insulin
secretion in pancreatic β-cells [30]. The observation of distinct
PKD pools at different intracellular sites, including Golgi,
cytoplasm, nucleus, mitochondria, and plasma membrane [31]
further complicates our understanding of the functions of
different PKD isoforms. In addition, various PKD isoforms
can differently localize within the same cell [31, 32] or shuttle
between cytosol and nucleus in response to particular stimuli
[33, 34]. Several reports imply PKDs in the organization of the
Golgi apparatus, regulating the ﬁssion of vesicles from the
trans-Golgi network (TGN) [23, 35]. PKD phosphorylates
several substrates at the Golgi, including PI4KIIIβ [36], cer-
amide transferring protein (CERT) [37], and oxysterol-binding
protein 1 (OSBP1) [38]. Phosphorylation of PI4KIIIβ results
in increased production of phosphatidylinositol-4-phosphate
(PI(4)P), which serves as a lipid “platform” to recruit lipid-
modifying enzymes and other regulating factors including
CERT and OSBP [36-38]. PKD-mediated phosphorylation of
CERT and OSBP1 results in decreased afﬁnity for PI(4)P,
making PKD an important sensor and mediator of lipid
homeostasis at the TGN [37, 38]. Vesicle budding by PKD is
thought to occur through its C1a domain mediated binding of
DAG at the outer leaﬂet of the TGN, followed by the
recruitment of phospholipase D (PLD) into the ARF1-PKD
complex. PLD generates phosphatidic acid (PA) from PtdCho,
which can be further converted into Lyso-PA (LPA). LPA can
form spontaneous curvatures, promoting vesicle budding [38].
Very recently our lab revealed that PKD2 and not PKD1, is a
core factor in the assembly of a functional multiprotein com-
plex at the TGN that regulates matrix metalloproteinase 2
(MMP2) secretion [39]. Importantly, these processes require
direct binding of PKD2 to ARF1 GTP-ase.
Many initial studies of PKD function did not specify
which PKD isoform was being referred to when role of the
kinase in the immune system was investigated. For instance,
Sidorenko and colleagues referred to PKD when they ﬁrst
revealed that T-cell receptor (TCR) cross-linking causes
activation of kinase [40]. Furthermore, PKD was described
to regulate different aspects of T-cell differentiation and
development of mature T-lymphocytes [40]. More knowl-
edge about the function of PKD isoforms in immune system
comes from Cantrell’s group [6, 41]. Using PKD2 and
PKD1 transgenic mice and PKD2 gene-trap mutant mice,
this study demonstrates that T- and B-lymphocytes speci-
ﬁcally express PKD2, but not PKD1 [6, 41]. Furthermore,
the catalytic activity of PKD2 is important for optimal T-
cell-dependent antibody response in vivo and effective
cytokine production after TCR engagement. In this context,
PKD2 kinase dead mutant T-lymphocytes fail to produce
interleukin-2 (IL-2) and interferon-γ (IFNγ) that are critical
for the adaptive immune response, a fact that suggests a role
of the kinase in controlling cytokine production [41]. PKD1
and PKD2 display similar subcellular trafﬁcking and acti-
vation kinetics in response to antigen receptor in A20
lymphoma B cells and leukemic Jurkat T-cell line [41-43].
Altogether, this study provides evidence that PKD2 has, at
least in some settings, a unique non-redundant role in
controlling T-cell function during adaptive immune
response and urges for further detailed investigations.
PKDs are also involved in vasculogenesis and myogenic
differentiation. Formation of vasculature involves the
assembly of endothelial cells into tubes that takes place
during embryogenesis [44]. In addition, members of PKD
family were reported to be involved in cardiac, skeletal, and
smooth muscle regulatory processes such as the mediation
of the hypertrophic response to angiotensin II or stimulation
of myocyte enhancer factor-2 (MEF2) activity in skeletal
muscle thus playing a crucial role in heart remodeling [45-
49]. Our lab examined the putative participation of PKDs to
myogenic differentiation by involving murine C2C12
myoblasts [50]. C2C12 differentiate rapidly and represent a
bona ﬁde in vitro model to study the differentiation of
myoblasts to myotubes. Although both PKD2 and PKD3
are predominantly expressed in C2C12 cells, only PKD2
was found to be catalytically active during the early phase
of differentiation to skeletal muscle cells [50]. Selective
depletion of PKD2 was sufﬁcient to prevent differentiation
of C2C12 cells [50]. By contrast, ectopic expression of the
kinase augments the initiation of myoblast differentiation by
activating Mef2D, a transcription activator that speciﬁcally
binds to the MEF2 element present in regulatory regions of
many muscle-speciﬁc genes that control cardiac morpho-
genesis and myogenesis [49].
The role of PKD2 in cancer
Cancer development is a complex process characterized by
various epigenetic and genetic modiﬁcations that promote
resistance to pro-apoptotic stimuli and confer insensitivity
Protein kinase D2
to antigrowth signals while sustaining angiogenesis and
immune surveillance. At the beginning of this millennium,
Hanahan and Weinberg deﬁned six hallmarks of cancer as
distinctive and complementary capabilities that enable
tumor growth and metastatic dissemination [51]. Cancer
cells are able to sustain proliferative signaling, evade tumor
suppressors, capable of invasion and metastasis, resist
apoptosis, promote angiogenesis, and enable replicative
immortality [51]. The conceptual progress made since the
year 2000 enabled not only describing new features crucial
to the six hallmark capabilities but also the acquisition of
novel hallmarks such as deregulation of the cellular meta-
bolism and avoiding immune destruction [52]. Furthermore,
the progress in technology and knowledge in cancer
research revealed, solidiﬁed, and extended the concept of
cancer biology in the sense that various factors such as the
tumor microenvironment have to be taken into account and
that cancer is not deﬁned by simply enumerating various
traits of tumor cells [52]. The heterogeneity in tumor
microenvironment, such as for instance the availability of
oxygen in different sections of a tumor, often leads to het-
erogeneity in the expression proﬁles of cancer cells within
that particular tumor. The variation in the expression sig-
natures in different regions of a tumor translates to a per-
turbation of regulatory signaling pathways, which makes
difﬁcult to ﬁnd a suitable therapy for the whole tumor. The
disruption of regulatory pathways in cancer cells is often a
source for genomic instability. Prime examples of deregu-
lated molecules are kinases [53], which have become the
most intensively pursued anticancer drug targets. Further-
more, kinases are placed at the crossroad/junction of mul-
tiple signaling pathways in the intricate intracellular
molecular circuitry governing cancer cell biology (Fig. 2).
Various kinases, including PKD2, show elevated protein
Fig. 2 PKD2 is involved in the regulation of multiple signaling
pathways, as well as in the integration of extracellular signals. Separate
circuits present the capability of PKD2 to orchestrate cancer cell
proliferation (blue), survival (green), angiogenesis (red), motility
(violet), and immune response (orange). This depiction is rather sim-
plistic, as there is considerable crosstalk between signaling pathways
comprising of PKD2-regulated molecules that participate to more than
one cancer hallmark (e.g., NF-κB). Furthermore, due to the fact that
each cancer cell is exposed to a variety of signals from its micro-
environment, each of these signaling pathways is connected to direct
(light blue) or indirect (light violet) signals originating from other cells
in the tumor microenvironment
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levels in tumors and might serve as cancer biomarkers.
Particularly high PKD2 expression was revealed in multiple
epithelial tumors, including pancreatic [21, 54, 55], color-
ectal [21, 56], prostate [57, 58], gastric [21, 59], breast
cancer [60, 61], and hepatocellular carcinoma [62]. High
expression of the kinase was also detected in glioblastoma
multiforme [63-65] and myeloid leukemia [27]. In the fol-
lowing, we will highlight the most important functions of
PKD2/PKD from the perspective of cancer hallmarks as
described by Hanahan and Weinberg [51, 52]. As an add-on
to these, newly described, as well as potential functions of
PKD2 are also presented.
Sustaining proliferative signaling
Normal tissues tightly regulate the production and secretion
of growth-promoting signals thereby ensuring the home-
ostasis and the maintenance of normal tissue architecture
and function. By contrast, tumor cells not only deregulate
such signals, but also enable signaling mechanisms con-
veyed largely by growth factors that control the progression
through the cell cycle, proliferation, and cell growth. For
instance, activation of the extracellular-signal regulated
kinase (ERK) pathway culminates with the transactivation
of various transcription factors implicated in growth, dif-
ferentiation, or mitosis. PKD has been shown to prolong
ERK signaling via phosphorylation of Ras and Rab inter-
actor 1 at Ser351 [66]. This induces 14-3-3 binding and
results in cytoplasmatic sequestration of this interactor,
which in turn potentiates the interaction between Ras and
the RAF kinase, potentiating ERK signaling [66]. Further-
more, although no direct evidence is present, a putative
participation of PKDs to PKC-mediated mitogen-activated
protein kinase (MAPK) signaling toward cell proliferation
should be also taken into account. Recent evidence suggests
that PKDs may play a role in colon cancer. PKD2 is the
major isoform in human colon cancer cells, whereas PKD1
is not expressed [67]. Inhibition of PKD with CRT0066101
had anti-proliferative effects on colon cancer cell lines and
on tumor growth in a HCT-116 xenograft model.
Mechanistically, effects were seen on AKT and ERK sig-
naling after inhibition or knockdown of PKD2 (but not
PKD3) [67]. A link between growth factor signaling and
cell cycle progression is provided by cyclin D1, which is
induced as a secondary response following mitogenic sti-
mulation. Recently, we showed that PKD2 abrogation in
glioblastoma cells induced the arrest of tumor cells in the
G1 phase of cell cycle, an event that was associated with
downregulation of cyclin D1 [63]. Moreover, abrogation
(both pharmacologic and genetic) of PKD2 prevented for-
mation of glioblastoma tumors in vivo and corresponded to
a signiﬁcantly reduced number of Ki67-positive tumor cells
[63]. Bernhart and colleagues extended these ﬁndings to a
xenograft mouse model using CRT0066101, a PKD family
inhibitor [64]. PKD2 silencing was associated with glioma
cell senescence via p53-dependent and -independent path-
ways [65]. Interestingly, although PKD2 overexpression
resulted in enhanced proliferation and migration of gastric
cancer cells, ectopic PKD1 had the opposite effects, sug-
gesting that expression level of PKD1/PKD2 may differ-
entially determine the behavior of gastric tumor cells. In a
similar manner, silencing of PKD2 but not of
PKD1 signiﬁcantly inhibited the proliferation of primary
human endothelial cells [68]. In addition, our lab could
demonstrate that PKD2 knockdown in pancreatic cancer
cells orthotopically implanted in mouse pancreas was
associated with impaired tumor growth [21], further sub-
stantiating a pro-proliferative role of PKD2. Ectopic PKD2
expression correlated with augmented expression of Golgi
phosphoprotein 3 (GOLPH3) [69], a membrane protein
located at the TGN that is involved in vesicle transportation
from Golgi to the cell membrane and in the glycosylation of
proteins. In this study, high level of GOLPH3 was asso-
ciated with the activation of phosphoinositide 3-kinase
(PI3K)-AKT and enhanced glioma proliferation [69]. Fur-
thermore, GOLPH3 was demonstrated to be a novel onco-
gene, which is commonly targeted for ampliﬁcation in
human cancers and regulates the response to rapamycin
[70]. Growth factors such as gastrin or IGF-1 stimulate
PKD activity in addition to their role in tumor cell growth
[71-73]. In addition, vascular endothelial growth factor
(VEGF) A-mediated PKD activation in endothelial cells
was reported to promote both proliferation and migration
[74, 75]. Many of these events involve PKC-mediated PKD
phosphorylation [17].
Resistance to cell death
Programmed cell death (apoptosis) serves as a natural bar-
rier to cancer development [52, 76, 77]. PKD1 was reported
to promote cell survival through the induction of anti-
apoptotic proteins survivin and cellular FLICE (FADD-like
IL-1β-converting enzyme)-inhibitory protein long form
(c-FLIPL) in pancreatic cancer cells [78]. PKD1 and
PKD2 protect cells from oxidative stress-induced cell death
by activating the transcription factor NF-κB [13, 28, 79,
80]. Interestingly, recent evidence suggests isoform-speciﬁc
regulation of PKDs in oxidative stress conditions, which is
paired by differential requirements for their signaling output
to NF-κB. Indeed, PKD2 signaling to NF-κB requires
phosphorylation of the kinase at Tyr438 in the human
myeloid leukemia cells [27]. However, in contrast to PKD1,
activation of NF-κB by PKD2 tyrosine phosphorylation is
independent of its catalytic activity. This may suggest that
PKD2 acts rather as a chaperone or scaffold and not as a
kinase in this process [27]. The production of reactive
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oxygen species (ROS) at the mitochondria, an event inti-
mately associated with a variety of human diseases [81-83],
has been demonstrated to initiate a mitochondria-to-nucleus
signaling cascade in which PKD plays a critical function
[80]. In this scenario, elevated mitochondrial ROS (mROS)
production results in PKD-dependent activation of NF-κB.
Translocation of NF-κB to the nucleus followed by induc-
tion of SOD2 leads to subsequent expression and accumu-
lation of manganese superoxide dismutase (MnSOD),
detoxiﬁcation of ROS, and ﬁnally increased cellular survi-
val [13, 80]. Together with other stimuli, ROS also induces
apoptosis signal-regulating kinase 1 (ASK1), an upstream
activator of c-Jun N-terminal kinase (JNK) and
p38 signaling cascades [84]. Using kinase inhibitors and
RNA interference, Zhang and colleagues identiﬁed PKD1
as s critical upstream mediator in H2O2-induced ASK1
activation and showed that 14-3-3 binding to PKD1 plays a
critical role in mediating H2O2-induced ASK1–JNK acti-
vation and endothelial cell apoptosis [85]. PKD1 can also
activate JNK downstream of death-associated protein kinase
(DAPK) (in a PKC-independent fashion), which results in a
pro-death signal and increased necrotic cell death [86].
Furthermore, Chen and colleagues demonstrated a pro-
survival and anti-apoptotic role of PKD2 in phorbol
myristate acetate (PMA)-induced apoptosis in androgen-
sensitive model of human prostatic carcinoma (LNCaP)
prostate cancer cells and identiﬁed ERK1/2 and NF-κB as
downstream effectors [87]. In this study, the authors suggest
that PKD2 may signal through non-redundant pathways to
modulate PMA-induced apoptosis. Recently, we found that
HSP90 chaperone interacts with and stabilizes PKD2 in
human cancer cells. Depletion of PKD2 following HSP90
inhibition was corroborated with tumor cell death in vitro,
as well as in vivo xenograft models [88]. Implication of the
kinase in cell death evoked by HSP90 inhibition together
with its ability to mediate stress-induced NF-κB activation
and cell survival [13] infer that PKD2 represents an
essential molecule involved in HSP90 signaling down to
NF-κB and is associated with chaperone-supported cancer
cell viability.
Role in EMT
Prior to intravasation, cancer cells often undergo the process
of epithelial-to-mesenchymal transition (EMT), an event by
which epithelial cells lose their polarization by reorganizing
their cytoskeleton and undergoing distinct biochemical
changes that allow transition to mesenchymal cells capable
to invade, resist apoptosis, and disseminate [89-91].
Although PKD1 was reported to inhibit EMT by controlling
the localization of the transcription factor Snail [92, 93] and
through E-cadherin phosphorylation [94, 95], the role of
PKD2 or PKD3 in the regulation of EMT is poorly
understood. Indirect evidence indicates that these two iso-
forms are potential positive regulators of EMT. Treatment
of MDA-MB-231 breast cancer cells with the selective pan-
PKD inhibitor CRT0066101 led to reduced expression of
EMT markers such as Snail, N-cadherin, MMP9, smooth
muscle actin (SMA), and vimentin [96]. Indeed, these data
are in line with our own ﬁndings showing that ectopic
expression of PKD2 in MDA-MB-231 breast or A549 lung
cancer cells correlates with acquisition of a mesenchymal
phenotype, loss of E-cadherin, and gain of vimentin
expression (Azoitei and Seufferlein, unpublished data).
Tumor necrosis factor (TNF)α plays an important role in
EMT in many cancer cells [97, 98] but also triggers the
association of TNFR1 and TRAF2, an event that is required
for PKD2 activation and EMT [62]. PKD2 was demon-
strated to contribute to TNFα-induced EMT and invasion by
increasing the activity of the PI3K/AKT/glycogen synthase
kinase 3 beta (GSK-3β)/β-catenin pathway [62]. Phos-
phorylation of GSK-3β by PKD2 was followed by trans-
location of β-catenin to the nucleus, regulation of T-cell
factor/lymphoid enhancer factor (TCF/LEF)-dependent
transcription and enhanced EMT and invasiveness in
hepatocellular carcinoma [62].
Invasion and metastasis
The multistep nature of invasion and metastasis has been
schematized as a succession of changes in cell biology,
beginning with local invasion that leads to intravasation of
cancer cells into proximal blood or lymphatic vessels. The
journey of cells with the blood/lymph stream to remote
distances is followed by the movement of cancer cells from
the vessel lumen into the parenchyma of remote tissues
(extravasation), establishment of small nodules of cancer
cells (micrometastasis), and ﬁnally the growth of micro-
metastatic lesions to macroscopic tumors [51, 52]. PKD1
and PKD2 isoforms show similar structural features and
fulﬁll a variety of overlapping functions [12, 99]. However,
their expression in various tumors is not identical. This
leads to the fact that tumor-relevant parameters are con-
trolled in an isoform-speciﬁc manner, sometimes even in an
opposing manner. For instance, PKD1 is downregulated in
invasive breast cancer cell lines suggesting an inhibitory
role of tumor cell motility [100-102]. The inhibition of
tumor cell motility by ectopic PKD1 was also demonstrated
in other tumor cells including pancreatic cancer cells. Our
lab has investigated the direct cell motility in a pancreatic
ductal adenocarcinoma (PDAC) model system and com-
pared the PKD1 and PKD2 invasive features in three-
dimensional extracellular matrix (ECM) culture [55, 103].
In this study, PKD1-regulated migration by interacting with
coﬁlin-phosphatase Slingshot-1L (SSH1L) at the cell per-
iphery and in dynamic membrane protrusions [55, 103].
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However, although on the one hand PKD1 stable knock-
down strongly enhanced invasive outgrowth from tumor
clusters, ectopic expression of PKD2 on the other hand
signiﬁcantly enhanced invasion of pancreatic cancer cells in
the surrounding the ECM [55, 103]. This is in line with
another study showing that abrogation of PKD2 in
doxorubicin-resistant Michigan Cancer Foundation-7
(MCF-7) breast cancer cells led to a signiﬁcant reduction in
cell migration [61]. ECM and cancer cells display an inti-
mate interaction. Thus, ECM can inﬂuence the behavior of
cancer cells, which in turn can cause breakdown of basal
membranes by enhanced secretion of MMPs [104]. We
identiﬁed in pancreatic cancer cells a novel isoform-speciﬁc
regulatory function for PKD2 upstream of MMP7 and
MMP9 in promoting invasion and angiogenesis both
in vitro and in vivo [55, 103]. Interestingly, MMP9 is
responsible for the release of VEGF [96, 104, 105], a
growth factor essential in tumor angiogenesis of whose
regulation by PKD2 will be discussed in more detail in the
angiogenesis section. The events of invasion and migration
promoted by PKD2-regulated MMPs and integrin expres-
sion were also reported in glioblastoma [64] and stromal
myoﬁbroblasts [106]. Interestingly, in contrast to the effects
of PKD2 on MMPs, PKD1 expression in osteosarcoma cells
has been shown to reduce invasiveness likely via the
decrease of MMP2 expression in these cells. PKD2 and
PKD3 also regulate migration and invasion via other
mechanisms. For example, in prostate cancer cells, PKD2
interacts with and phosphorylates inhibitor of nuclear factor
kappa-B kinase subunit beta (IKKβ) while is responsible for
inhibitory kappa B protein alpha (IκBα) degradation [58].
The fact that subsequent nuclear translocation of p65 was
primarily dependent on PKD2 rather than PKD3, suggests
that PKD2 may play a role in classical NF-κB-mediated cell
invasion [58]. In addition, PKD2 also promotes invasion
and tumor cell migration by phosphorylating the splice
variant of calcium and integrin-binding protein 1 (CIB1a)
[107]. Several studies revealed additional substrates for
PKDs at the leading edge such as Ena/VASP-like protein
(EVL)-1 [108], vasodilator-stimulated phosphoprotein
(VASP) [109], and cortactin [110].
Induction of angiogenesis
In order to grow, tumors require oxygen and nutrients, as
well as the possibility to evacuate metabolic wastes and
CO2. Angiogenesis, the generation of tumor-associated
neovasculature from pre-existing vessels, is the process that
ensures all these needs. A large body of evidence demon-
strates that the angiogenic switch is orchestrated by coun-
tervailing factors that either oppose or induce angiogenesis
[111]. A well-known inducer of angiogenesis is VEGF-A,
which governs the growth of new blood vessels both in
physiological and pathological conditions [112]. VEGF
gene expression can be regulated both by hypoxia and by
oncogene signaling [113, 114]. Many epithelial tumors are
characterized by their ability to grow in hypoxic environ-
ment [115-117]. This usually requires upregulation of
hypoxia inducible factor 1-alpha (HIF-1α), a transcription
factor involved in the cellular response to hypoxia.
Hypoxia-mediated VEGF-A expression can be mediated by
molecular mechanisms dependent on PKCs [118]. Indeed,
our experiments revealed a marked increase in PKD acti-
vation under hypoxic conditions [21]. Our lab and others
have previously shown that PKD2 modulates the expression
of the orphan-nuclear receptor TR3/Nur77, a protein that
has been reported to be a stabilizer of HIF-1α and mediator
of VEGF expression [21, 119, 120]. Later experiments
demonstrated that hypoxia-induced VEGF-A expression
and secretion requires expression of TR3 in pancreatic
cancer cells, which in turn crucially requires PKD2 [21].
Furthermore, mere abrogation of PKD2 in the tumor cells
prevented tumor angiogenesis in two in vivo experimental
models, chicken CAM and orthotopic pancreatic tumor
xenograft in nude mice [21]. Interestingly, PKD2 is highly
expressed not only in tumor cells but also in endothelial
cells [21]. Treatment of mice with Vivo-Morpholino splice-
blocking oligonucleotides targeting murine PKD2 resulted
in impaired blood vessel formation, which resulted in the
formation of smaller tumors [21]. Similarly, depletion of
PKD2 resulted in decreased basal and VEGF-A-induced
endothelial cell sprouting [21]. These data are in line with
the fact that PKD2, but not PKD1, is expressed in primary
human endothelial cells from various tissues and is required
for the expression of VEGFR-2 in endothelial cells [68].
Moreover, in endothelial cells PKD2 is activated by VEGF
via tyrosine phosphorylation [74, 75] and contributes to
endothelial cell proliferation, migration, and angiogenesis
in vitro [68]. A recent study identiﬁed PKD2 as a crucial
molecule in the stabilization of BCL6-associated zinc-ﬁnger
(BAZF) protein upon induction by VEGF-A [121]. VEGF-
A-induced BAZF forms a complex with cullin 3, an E3
ubiquitin ligase that degrades CBF-1, a transcription factor
implicated in Notch signaling [122, 123]. To note, angio-
genic sprouting is tightly regulated by the Notch signaling
circuit of the VEGFR-Notch ligand, Dll4 [123-125]. Inter-
estingly, HSP90 inhibitors 17-AAG and PU-H71 inhibited
PKD2-mediated stabilization of BAZF-mRNA [126, 127].
This is in line with our experiments demonstrating that the
HSP90 chaperone supports tumor growth and angiogenesis
through PKD2 protein stabilization [88]. In this study, we
have identiﬁed PKD2 as a novel client of the chaperone and
demonstrated that ectopic expression of PKD2 restored
tumor cell viability and vascularization after HSP90 phar-
macologic inhibition in vivo. These results support PKD2
degradation through HSP90 inhibition as a potential
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strategy to approach two important cancer features, angio-
genesis, and cell viability, with one drug. HSP90 inhibitors
have been reported to indirectly regulate HIF-1α [126-128].
The fact that the chaperone interacts both with HIF-1α [128]
and PKD2 [88] likely implicates PKD2 in tumor angio-
genesis coordinated by HSP90/HIF-1α. Indeed, ectopically
expressed PKD2 partially restores HIF-1α protein levels,
HIF-1α transcriptional activity, and secreted VEGF-A
levels after HSP90 inhibition [88]. Although Choi and
colleagues demonstrated that TR3/Nur77 is activated by
HIF-1α [129], in the same year Yoo et al. revealed that
TR3/Nur77 stabilizes HIF-1α [130]. It still remains to be
elucidated whether PKD2 restores HIF-1α through the
induction of TR3/Nur77 or whether PKD2 activates TR3/
VEGF-A by stabilizing HIF-1α. As the transcription factor
NF-κB and its target gene VEGF-A are activated by
hypoxia, HSP90, and PKD2 [88, 131], it is possible that
NF-κB signaling might be connected to the hypoxic
response governed by HSP90-PKD2. However, in this
study PKD2 only marginally restored hypoxia-induced NF-
κB promoter activity during chaperone inhibition, suggest-
ing that additional factors/clients are necessary to transmit
HSP90’s angiogenic signals via NF-κB pathway [88].
Whether PKD2 activates NF-κB/VEGF-A via upregulation
of HIF-1α or whether interaction with other molecules is
required (such as IKK [89]) is not fully understood so far.
Furthermore, our lab has identiﬁed a novel splice variant of
CIB1a as a potential substrate of PKD2 [107]. PKD2
interacts with and phosphorylates CIB1a at Ser115, which is
associated with tumor cell growth and angiogenesis [107].
Another process through which PKD2 controls tumor
angiogenesis is secretion of MMPs. Although PKD2 con-
trols secretion of MMP7 and MMP9, only MMP9 was
shown to augment the release of extracellular matrix-bound
VEGF-A [107]. The fact that PKD2 controls angiogenesis
via regulation of molecules such as CIB1a or MMPs, shown
to promote also tumor cell invasion, indicates again the
versatility and the implication of this kinase in different
aspects of cancer biology.
Regulation of innate and adaptive immune defenses
Human and mouse T- and B-lymphocytes, thymocytes, and
spleen cells predominantly express PKD2, but not PKD1 or
PKD3 [6]. PKD2 catalytic activity is important for effective
cytokine production after TCR stimulation. TCR stimulation
results in the translocation of PKD2 to the nucleus, an event
associated with the induction of IL-2 and IFNγ production,
which play a critical role in adaptive immune responses. TCR
engagement induces DAG production and activates PKCs
[132-134], which were shown to phosphorylate Ser707 and
Ser711 in PKD2. The failure of catalytically inactive PKD2
T-lymphocytes to effectively produce IL-2 and IFNγ
suggests that PKD2 has a unique role in controlling T-cell
functions during adaptive immune responses [6]. IFNα-sti-
mulated activation of PKD2 requires its phosphorylation at
Tyr438, a molecular event also necessary for efﬁcient serine
phosphorylation and degradation of IFNAR1 and conse-
quently restriction of magnitude and duration of cellular
responses to type 1 interferon including IFNα/β [135]. As
IFNα/β are used in treatment of infections, multiple sclerosis,
and cancers, deciphering the mechanisms of ligand-inducible
activation of PKD2 and its recruitment to the receptor may be
of clinical relevance [135]. Notably, IFNα/β antagonizes the
process of angiogenesis that is stimulated by VEGF, and both
counteracting stimuli activate PKD2. VEGF-mediated
recruitment of PKD2 to the IFNAR1 is followed by phos-
phorylation, ubiquitination, and degradation of the receptor
subsequent to inhibition of type 1 IFN signaling. The fact that
degradation of the IFN1R is required for efﬁcient
VEGF-stimulated angiogenesis [135] adds another level of
complexity to the role of PKD2 in cancer progression.
Interestingly, PKD2 was recently also implicated in a path-
way that drives PDL-1 surface expression downstream of
IFN-γ in oral squamous carcinoma, which argues for the
combination of (PKD) targeted therapies with the emerging
immune therapies [136]. Several other studies revealed that
PKD2 does not only play a role in adaptive but also in the
innate immune responses. Natural killer (NK) cells were
reported to establish the ﬁrst line of defense against tumor
and virus-infected cells [137, 138] and their activation is
subdivided in two mechanisms: natural toxicity and CD16-
mediated antibody-dependent cellular toxicity. Engagement
of CD16 was demonstrated to cause responses in various
kinases including PKD2, indicating a role in the signal net-
work orchestrating NK cell effector functions [139, 140]. In
this study, application of CID755673, a selective inhibitor of
PKD family members, resulted in a signiﬁcant dose-
dependent reduction of NK cell degranulation markers and
cytokine release. These data underline PKD2 as a signaling
component in NK cell activation and therefore as a molecule
with a potential role in cancer immunosurveillance.
Regulation of protein transport and secretion
Altered vesicular sorting or transport of speciﬁc proteins
has been repeatedly linked to a broad range of cancer types
and therefore represents a promising target for therapeutic
interventions [141]. PKD isozymes are instrumental in the
regulation of protein secretion from the TGN to the plasma
membrane [142] by acting as key regulators of membrane
ﬁssion of transport carriers at the TGN [25, 143-145]. All
three isoforms of PKD have been implicated in secretory
vesicle biogenesis [17, 26]. In this context, a substantial
function of PKD1 in the secretion of several tumor-
promoting factors including IL-6, IL-8 and growth-related
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oncogene-α in endothelial cells and epithelial cancer cell
lines has been characterized [146-148]. PKD2, on the
other hand, has been shown to mediate constitutive
secretion of MMPs (MMP7 and MMP9) [55], which have
both been linked with overall survival in gastric cancer
[149] and more generally in tumor metastasis. A vital
function of PKD2 was also described in the regulation of
peptide hormone release, namely of the neuroendocrine
tumor marker chromogranin A, from carcinoid derived
pancreatic cells [25]. Furthermore, the isoform PKD3
plays a critical role in the secretion of tumor-promoting
factors, for example, in prostate cancer [150]. It is
understood that the function of PKDs in vesicle formation
is, at least partially, mediated by the phosphorylation and
thereby activation of substrate proteins like
phosphatidylinositol-4 kinase III β and ceramide transfer
protein CERT, followed by changes within the local lipid
environment [151, 152]. It is known that PKDs are asso-
ciated with the TGN by binding to DAG via their C1a
zinc-ﬁnger domain. PKD2 directly interacts via Pro275 in
its C1b domain with ARF1 [153], a GTPase that directly
regulates the assembly of budding vesicles by recruiting
coat (COPI) and clathrin adaptor proteins to the TGN and
by activating lipid-modifying enzymes [154-159]. Muta-
tion of P275 prevents PKD2 localization to the TGN,
resulting in a severely reduced secretion of cargo proteins
[153]. Interestingly, it was shown that PKD dimerization is
essential for effective DAG dependent secretion of mem-
braneous cargo [160]. Furthermore, a recent study has
identiﬁed a protein complex at the TGN comprising
PKD2, ARF1, and the Arf-like GTPase Arl1 [39]. PKD2
acts as a scaffold protein, anchoring the complex at the
TGN and recruiting effector proteins like the BAR domain
protein arfaptin 2, independent of its kinase function and
vital for constitutive secretion processes such as the
transport of MMPs [39].
Potential regulation of energy metabolism
The uncontrolled growth of tumors does not only involve
deregulated cell proliferation but also adjustments in the
energy metabolism. In the early stages of cancer devel-
opment, tumor cells proliferate beyond the limit of diffu-
sion and face hypoxia, a low oxygen environment reported
to prevent energy production by oxidative phosphorylation
[161]. The increasing demand for energy by fast pro-
liferating tumor cells in hypoxic microenvironment trig-
gers rapid metabolic reprograming [161-163]. Upon
activation of HIF-1α/HIF-2α transcription factors or by
Ras oncoproteins, cancer cells undergo a “metabolic
switch” by using glycolysis to efﬁciently maintain cellular
bioenergetics in restrictive growth conditions [162-165].
To date, there is no direct evidence on the role of PKD2 in
the process of aerobic glycolysis. However, an indirect
role of the kinase in energy metabolism could be envi-
saged upon regarding its involvement in the regulation of
HIF-1α. Indeed, we demonstrated that abrogation of PKD2
in pancreatic cancer cells resulted in impaired hypoxia-
induced HIF-1α accumulation and transcriptional activity
and was associated with decreased tumor growth [21].
Although further and detailed investigations are required,
these results might represent the ﬁrst steps in revealing a
novel function for PKD2, namely reprogramming the
energy metabolism.
PKD inhibition in cancer therapy
The emergence of PKD2 as a putative therapeutic target for
cancer has encouraged the development of potent, selective,
and cell-permeable small-molecule inhibitors. Several small-
molecule inhibitors such as CID755673 and analogs [166],
2,6-naphthyridine and bipyridyl and analogs [167-169], 3,5-
diarylazoles [170], CRT0066101 [56], pteridine [171], and
CRT5 [172] were demonstrated to inhibit PKD in vitro and
in intact cells. Treatment with CID755673 resulted in a sig-
niﬁcant reduction of NK cell granulation markers and cyto-
kine release in peripheral blood mononuclear cell population
[138]. This study underlines the importance of CaMKII for
NK cell signaling and suggests PKD2 as a novel signaling
component in activation of NK cells and cancer immuno-
surveillance. On the other hand, treatment with CRT0066101
was reported to efﬁciently block the growth of pancreatic and
colon tumor xenografts in mice and was associated with G2-
M phase arrest and induction of apoptosis [56], whereas
CRT5 decreased VEGF-induced endothelial migration, pro-
liferation, and tubulogenesis [172]. Tandon and colleagues
described two new pyrazolopyrimidine pan-PKD inhibitors,
namely 1-NA-PP1 and IKK-16 that potently inhibited pros-
tate tumor cell migration and invasion [173]. Recently, a
more potent PP1 derivative was synthesized showing the
potential for this class of molecules as PKD inhibitors [171].
In a targeted screen of 80 chemically diverse compounds,
Tandon et al. identiﬁed SD-208 that showed moderate inhi-
bitory activity towards PKD with an IC50 of 106 nM in vitro
[171]. The (orally available) compound could inhibit prostate
cancer cell survival, proliferation, and invasion in vitro and
tumor growth in a xenograft model of PC3 cells [171]. PKD2
can be also indirectly targeted by using HSP90 chaperone
inhibitors [88] currently under clinical evaluation such as PU-
H71, a water-soluble member of the purine class of HSP90
inhibitors [174] or STA-9090, a resorcinol-containing tria-
zole molecule [175]. We have reported that HSP90-
dependent PKD2 stabilization results in the activation of
NF-κB and its target VEGF-A, which promotes tumor cell
proliferation and increased vascularization in hypoxic tumors
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[88]. All these initial steps in deciphering the intricate
molecular network in which PKD2 is implicated, provide a
rational basis for the design and development of new inhi-
bitors that, alone or in combination cocktails with currently
available anticancer drugs, may improve the clinical out-
come. However, before any PKD-based therapies can be
implemented in the clinic, the expression level and pattern of
each PKD isoform has to be accurately determined so that the
appropriate treatment regimen can be decided upon.
Conclusion and perspectives
There is a compelling body of evidence involving PKD2 in
the regulation of multiple signaling pathways, as well as in
the integration of extracellular signals that modulate cancer
cell morphology, migration, proliferation, and survival
(Fig. 2, Table 1, Fig. 3). Various functions of PKD2 in
common human tumors were summarized in this review
from the perspective of cancer hallmarks described and
Table 1 The table presents the
cancer-related functions of each




Tumor type Activation/regulation Reference
Proliferation Pancreatic [54]
Prostate MMP2/MMP9 [177]
Invasion Breast MMP [97]
PKD1 Tumor cell viability Prostate ERK1/2, NF-κB [87]
Pancreatic Cortactin/SSH1L [55, 110]
Breast MMP [97]
EMT Prostate Snail [178]
Pancreatic HIF-1α/VEGF [21]
Glioma GOLPH3/AKT [69]
Proliferation Glioblastoma Cyclin D1/p53 [63-65]
Invasion Pancreatic MMP/Snail [55, 103]
Neuroendocrine [176]
Prostate NF-κB/HDAC1/uPA [58]
Migration/motility Pancreatic CIB1a [107]
Breast cancer [61]
Tumor cell viability Myeloid leukemia NF-κB/Bcr-Abl [27]
PKD2 Prostate ERK1/2/NF-κB [87]
Colon pancreas lung HSP90/NF-κB [88]
EMT Hepatocellular PI3K/GSK-3β/β-catenin [62]




Pancreas colon lung HIF-1α/NF-κB/HSP90 [21, 88]
Prostate ERK1/2, NF-κB [87]
Secretion Neuroendocrine Chromoganin A [22, 25]
Pancreatic MMP7/MMP9 [55, 93]
Tumor angiogenesis Pancreatic HIF-1α/VEGF-A/BAZF [21, 120, 121]
Pancreatic CIB1a/MMP9 [107]
Colon lung HSP90/HIF-1α/NF-κB/VEGF-A [88]
Proliferation Prostate MMP2/MMP9 [177]
Breast mTORC-S6K1 [179]
PKD3 Tumor growth Prostate Akt/ERK1-2 [57]
Breast [60]
Invasion Prostate NF-κB/HDAC1/uPA [58]
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revisited by Hanahan and Weinberg in years 2000 and
2011, respectively. Newly described, as well as potential
functions of PKD2, not necessarily regarded as a cancer
hallmark, are also presented. While multiple studies over
the last 16 years identiﬁed previously unrecognized
mechanisms of action for PKD2, there is still need for a
better understanding of differential kinase expression,
isoform-speciﬁc functions, and activation of different iso-
forms and molecular cross-signaling. Delineation of
potential compensatory actions between various PKD iso-
forms in a given tumor will help to enhance the therapeutic
prospects of PKDs in a successful combinatorial molecular
therapy approach.
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